NEXTCURE INC. - COMMO

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

12 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

07 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

05 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

31 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

03 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

21 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

NextCure to Present at the JMP Securities Life Sciences Conference

09 May 2023 06:00:01 By Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

04 May 2023 15:05:02 By Nasdaq GlobeNewswire

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

02 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

NextCure to Present at SVB Securities Global Biopharma Conference

07 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

NextCure to Present at Upcoming Investor Conferences

22 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

15 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

07 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

03 Nov 2022 15:15:00 By Nasdaq GlobeNewswire

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

03 Nov 2022 08:15:00 By Nasdaq GlobeNewswire

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

27 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

05 Oct 2022 07:15:00 By Nasdaq GlobeNewswire

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

04 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

22 Sep 2022 07:00:01 By Nasdaq GlobeNewswire